Preventive effect of recombinant human lactoferrin in a rabbit preterm delivery model

Hasegawa, Akitoshi; Otsuki, Katsufumi; Sasaki, Yasushi; Sawada, Masamichi; Mitsukawa, Kaori; Chiba, Hiroshi; Nagatsuka, Masaaki; Okai, Takashi; Kato, Akifumi

doi:10.1016/j.ajog.2005.01.013

Cited by 23 publications

(21 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hasegawa et al have previously demonstrated that LPS-induced IL-6 production in human amnion cells was significantly inhibited by the physiological concentration of Lf in vitro, suggesting that increased levels of Lf under infectious conditions might serve as a self-defense mechanism for both antibacterial and anti-cytokine actions (32). Later, the same research group reported that the transcervical administration of Lf to pregnant rabbits, previously inoculated with E. coli, improved fetal survival and prolonged pregnancy (32).…”

Section: Discussionmentioning

confidence: 99%

Influence of lactoferrin in preventing preterm delivery: A pilot study

Giunta¹,

Giuffrida²,

Mangano

et al. 2011

Mol Med Report

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Influence of lactoferrin in preventing preterm delivery: A pilot study

Giunta¹,

Giuffrida²,

Mangano

et al. 2011

Mol Med Report

View full text Add to dashboard Cite

“…Lactoferrin (encoded by Ltf ), an iron-binding glycoprotein in the transferrin family, has been detected in vaginal secretions and amniotic fluid [20,21,22,23,24,25,26,27,28]. This protein modulates inflammatory and immune responses to kill bacteria, viruses and fungi [29].…”

Section: Discussionmentioning

confidence: 99%

“…This protein modulates inflammatory and immune responses to kill bacteria, viruses and fungi [29]. Recombinant human lactoferrin has a positive role in the prevention of bacteria-induced preterm delivery in rabbit and mouse models [23,25,26,28,30]. Furthermore, vaginal administration of lactoferrin plays a role in reducing the risk of preterm birth for women with shortened cervical length and elevated interleukin 6 levels [31], being especially effective for women with refractory vaginitis recurring preterm delivery [21].…”

Section: Discussionmentioning

confidence: 99%

Transcriptomic Insights into the Response of Placenta and Decidua Basalis to the CpG Oligodeoxynucleotide Stimulation in Non-Obese Diabetic Mice and Wild-Type Controls

Liu

Guo

Qin

et al. 2016

IJMS

View full text Add to dashboard Cite

Intrauterine infection is one of the most frequent causes of miscarriage. CpG oligodeoxynucleotide (CpG ODN) can mimic intrauterine infection. CpG ODN-induced embryo-resorption was observed consistently in the NK-cell deficient non-obese diabetic (NOD) mice but not in the wild-type (WT) mice. To elucidate the molecular mechanisms of differential pregnancy outcomes, differentially expressed genes (DEGs) in the placenta and decidua basalis was revealed by RNA-Seq with CpG ODN or control ODN treatment. Common DEGs in the WT and NOD mice were enriched in antimicrobial/antibacterial humoral responses that may be activated as a primary response to bacterial infection. The susceptibility to CpG ODN-induced embryo-resorption in the NOD mice might mainly be attributed to M1 macrophage polarization and the immunodeficient status, such as the down-regulation in antigen processing and presentation, allograft rejection, and natural killer cell mediated cytotoxicity. In contrast, the WT mice with normal immune systems could activate multiple immune responses and be resistant to CpG ODN-induced embryo-resorption, such as M2 macrophage differentiation and activation regulated by complement component C1q and peroxisome proliferation-activated receptor (PPAR) signaling pathways. Collectively, this study suggests that the immunodeficient status of NOD mice and the macrophage polarization regulated by C1q and PPAR signaling might be the basis for differential pregnancy outcomes between the NOD and WT mice.

show abstract

“…Lactoferrin has an inhibitory effect on lipopolysaccharide-induced production of inflammatory cytokines [tumor necrosis factor-α, interleukin (IL)-1β, IL-6, and IL-8 messenger RNA] and interferes with nuclear factor-κB activation in monocytic cells [26,27]. Additional functions of lactoferrin have been reported, such as neutrophil and macrophage activation [28], regulation of specialization and function of lymphocytes [29], activation of natural killer cells [30], control of oxidation injury [29], and down-modulation of ongoing immune-inflammatory responses during preterm delivery [31]. Moreover, lactoferrin exhibits a synergistic effect with immunoglobulin A, lysozyme, antibiotics, and drugs, which helps in the eradication of microorganisms [32].…”

Section: Introductionmentioning

confidence: 99%

Bacterial biota of women with bacterial vaginosis treated with lactoferrin: an open prospective randomized trial

Pino

Giunta

Randazzo

et al. 2017

Microbial Ecology in Health and Disease

View full text Add to dashboard Cite

Background: Bacterial vaginosis is the most frequent condition associated to the vaginal microbiota imbalance, affecting about the 40–50% of women in the world. Even if antibiotics are effcetive for bacterial vaginosis treatment a long-term recurrence rates, higher than 70%, is recorded. Lactoferrin is an iron-binding glycoprotein with bacteriostatic and bactericidal properties. It owns the ability to protect the host against infection, by binding and regulating the iron needed for the bacterial proliferation.Objective: The present study was an open prospective randomized trial (registration no. SHI-EVE-2014.01) aimed at characterizing the bacterial biota of women affected by bacterial vaginosis (BV) and assessing the effects of two different lactoferrin concentrations (100 mg and 200 mg vaginal pessaries) on the composition and dynamics of the vaginal bacterial biota.Design: Sixty women with BV were recruited and randomized into two groups to receive lactoferrin pessaries for 10 days. Clinical evaluation was based on Amsel criteria and Nugent scores. Culture-dependent methods and Ion Torrent PGM sequencing of the 16S rRNA gene were applied to study in depth the overall structure of the vaginal bacterial biota and its dynamics during the treatment.Results: Vaginal lactoferrin administration modified the vaginal microbiota composition in patients with BV. During treatment, both 100 mg and 200 mg lactoferrin vaginal pessaries significantly decreased the occurrence of bacteria associated with BV, such as Gardnerella, Prevotella, and Lachnospira, and increased the occurrence of Lactobacillus species. The bacterial biota balance was maintained up to 2 weeks after treatment only in women treated with 200 mg lactoferrin pessaries.Conclusions: This study indicates that lactoferrin could be proposed as an alternative therapeutic approach for BV. Our data showed, for the first time, the dominance of Lactobacillus helveticus species during and after vaginal lactoferrin treatment.

show abstract

Preventive effect of recombinant human lactoferrin in a rabbit preterm delivery model

Cited by 23 publications

References 36 publications

Influence of lactoferrin in preventing preterm delivery: A pilot study

Influence of lactoferrin in preventing preterm delivery: A pilot study

Transcriptomic Insights into the Response of Placenta and Decidua Basalis to the CpG Oligodeoxynucleotide Stimulation in Non-Obese Diabetic Mice and Wild-Type Controls

Bacterial biota of women with bacterial vaginosis treated with lactoferrin: an open prospective randomized trial

Contact Info

Product

Resources

About